Argus Research Maintains Buy on CVS Health, Raises Price Target to $114
Argus Research analyst Steve Silver maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $104 to $114.
Read original at benzingaStocks · News reference
Barclays Maintains Overweight on CVS Health, Raises Price Target to $108
Barclays analyst Andrew Mok maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $106 to $108.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 1:19 PM
- Checked
- Aug 6, 2026, 1:19 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Costco Is Getting Into Medicare — Here’s What Its New Health Insurance Plans Could Mean for Seniors
Costco plans a limited Medicare rollout with SCAN Group as insurers face rising costs and regulatory scrutiny.
Read original at benzinga8-K filing — CVS HEALTH Corp (CVS)
Filed: 2026-08-17 AccNo: 0001193125-26-354096 Size: 159 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarViking Global Bets Big On SpaceX While Ditching CoreWeave, Alphabet in Q2
Viking Global Investors' second-quarter 13F shows new stakes in SPCX, MS, QCOM, CVS and exits in CRWV and GOOGL.
Read original at benzinga